Tara-002 in Lymphatic Malformations

Tara-002 in Lymphatic Malformations

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is no longer recruiting.

Description

This study is for people with growing abnormal lymph vessels called lymphatic malformations (LMs). This study has 3 parts and involves taking a study drug called TARA-002. The purpose of this study is to find out if the study drug is safe and effective (can help) people with LMs. Participants receive the study drug by injection and will complete other research assessments throughout the study.

Eligibility and criteria
IRB Number:
23-021092
Eligible age range:
6 months - 17 years
Clinical trial phase:
Phase II
Official title:
A Phase 2a/b Single Arm Open Label Study to Evaluate the Safety and Efficacy of Intracystic Injection of TARA-002 in Participants Between 6 Months to Less than 18 Years of Age for the Treatment of Macrocystic and Mixed Cystic Lymphatic Malformations (STARBORN-1)

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.